Oxford Glyco delays vote on CAT merger
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Oxford GlycoSciences, the company at the centre of European biotech's first hostile bid battle, has postponed a shareholder meeting to vote on its agreed merger with Cambridge Antibody Technology.
The company is continuing to recommend CAT's all-paper deal over a higher cash offer from Celltech, but the OGS chief executive David Ebsworth said yesterday the adjournment would "allow adequate time to explore options for maximising value".
CAT sources said it is still "chewing over" the possibility of adding a cash element to its existing all-share offer, which was valued last night at £85m.
Insiders at Celltech said the decision amounted to OGS abandoning its recommendation of the current CAT offer, and predicted its £101m cash bid would now succeed.
CAT argues that its deal with OGS will create a seriousrival to Celltech, with enough cash to buy in and develop exciting new drugs. Celltech's offer – which the company itself has termed opportunistic – will bring it OGS's library of human proteins and cash pile of £130m, which will cover the costs of the acquisition.
OGS shares stayed stubbornly above the Celltech offer, unchanged at 195p. Investors continue to bet an increased CAT offer may push Celltech into raising its bid, or that a third predator will emerge. Immuno-Designed Molecules, a private French group, is believed to be considering a bid.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments